Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 14/20 | 0.67 |
| ▸ | PDE4A | P27815 | 8/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6690018 | 0.81 | TNF (0.78) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12898667 | 0.80 | ALDH1A1 (0.52) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6697290 | 0.80 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7455983 | 0.80 | TNF (0.72) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7400893 | 0.79 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4863180 | 0.79 | TNF (0.69) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6280398 | 0.78 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6287593 | 0.78 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4864210 | 0.78 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17916053 | 0.77 | TNF (0.53) | TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1389103-A4 | SYNTHESIS AND EVALUATION OF NOVEL PHTHALIMIDE MIMICS AS ANTI-ANGIOGENIC AGENTS | UNIV VIRGINIA (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040122030-A1 | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2004-06-24 | — | — | US | disclosed |
| EP-1389103-A2 | SYNTHESIS AND EVALUATION OF NOVEL PHTHALIMIDE MIMICS AS ANTI-ANGIOGENIC AGENTS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002086078-A2 | SYNTHESIS AND EVALUATION OF NOVEL PHTHALIMIDE MIMICS AS ANTI-ANGIOGENIC AGENTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122030-A1 | Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic | KDR, FLT4, FLT1 | TNF 1863/4885PDE4A 3385/4885PDE4B 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.